Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples

Kumano, Keiki; Arai, Shunya; Hosoi, Masataka; Taoka, Kazuki; Takayama, Nobuki; Otsu, Makoto; Nagae, Genta; Ueda, Koki; Nakazaki, Kumi; Kamikubo, Yasuhiko; Eto, Koji; Aburatani, Hiroyuki; Nakauchi, Hiromitsu; Kurokawa, Mineo

doi:10.1182/blood-2011-07-367441

Cited by 145 publications

(153 citation statements)

References 56 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Generation of iPSCs from other cancer types is necessary to develop relevant in vitro models for carcinogenesis. [73] , 2013 CML iPSCs from CML cell lines and primary patient samples Carette et al [70] , 2010 Kumano et al [72] , 2012 JML Derived iPSCs from 2 JML patients Gandre-Babbe et al [75] , 2013 Gastrointestinal cancer Generated iPSCs from multiple GI cancer cell lines Miyoshi et al [69] , 2010 Glioblastoma iPSCs generated from glioblastoma-derived neural stem cells Stricker et al [76] , 2014; Stricker et al [77] , 2013…”

Section: Resultsmentioning

confidence: 99%

“…to imatinib and demonstrated phenotypic similarities to CML stem cells. This cell population may therefore be useful to interrogate the role of stem cells in CML and the mechanisms underlying the development of resistance [72] . iPSCs and pancreatic ductal adenocarcinoma iPSCs have also been used to study pancreatic ductal adenocarcinoma (PDAC), which currently has no suitable model.…”

Section: Ipscs and Chronic Myeloid Leukemiamentioning

confidence: 99%

“…Interestingly, despite the sensitivity of the KBM7 cell line to imatinib, the iPSCs generated lost their BCR-ABL dependence and became resistant to imatinib [70] , the tyrosine kinase inhibitor which targets the BCR-ABL protein which defines CML [71] . In a further study, Kumano et al [72] derived iPSCs from primary cultures from two CML patients and showed stem cell morphology and markers along with the ability to differentiate into haematopoietic progenitors which expressed the BCR-ABL fusion protein. Again, these iPSCs were generated from imatinib-sensitive patients but became resistant.…”

Section: Ipscs and Chronic Myeloid Leukemiamentioning

confidence: 99%

See 2 more Smart Citations

Using induced pluripotent stem cells as a tool for modelling carcinogenesis

Curry

Moad

Robson

et al. 2015

WJSC

View full text Add to dashboard Cite

Cancer is a highly heterogeneous group of diseases that despite improved treatments remain prevalent accounting for over 14 million new cases and 8.2 million deaths per year. Studies into the process of carcinogenesis are limited by lack of appropriate models for the development and pathogenesis of the disease based on human tissues. Primary culture of patient samples can help but is difficult to grow for a number of tissues. A potential opportunity to overcome these barriers is based on the landmark study by Yamanaka which demonstrated the ability of four factors; Oct4, Sox2, Klf4, and c-Myc to reprogram human somatic cells in to pluripotency. These cells were termed induced pluripotent stem cells (iPSCs) and display characteristic properties of embryonic stem cells. This technique has a wide range of potential uses including disease modelling, drug testing and transplantation studies. Interestingly iPSCs also share a number of characteristics with cancer cells including self-renewal and proliferation, expression of stem cell markers and altered metabolism. Recently, iPSCs have been generated from a number of human cancer cell lines and primary tumour samples from a range of cancers in an attempt to recapitulate the development of cancer and interrogate the underlying mechanisms involved. This review will outline the similarities between the reprogramming process and carcinogenesis, and how these similarities have been exploited to generate iPSC models for a number of cancers. Core tip: Human induced pluripotent stem cells (iPSCs) represent a novel method for studying the mechanisms of cancer development and progression. Recently, a number of studies have generated iPSCs from human cancer cells and cell lines, which can then be used as a model for carcinogenesis. This review outlines the similarities that exist between pluripotent and malignant cells and summarizes available studies that have generated iPSC models of cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Ipscs and Chronic Myeloid Leukemiamentioning

confidence: 99%

Section: Ipscs and Chronic Myeloid Leukemiamentioning

confidence: 99%

See 1 more Smart Citation

Using induced pluripotent stem cells as a tool for modelling carcinogenesis

Curry

Moad

Robson

et al. 2015

WJSC

View full text Add to dashboard Cite

show abstract

“…Disease Modeling Using Patient-Specific iPSCs To date, several patient-specific iPSC lines have been generated from patients with a wide variety of mainly monogenetic, early-onset diseases such as neurologic disorders, 44,45) heart disease, 46,47) metabolic disease, 48) hematologic disorders, 49) mitochondrial disease, 50) chromosomal abnormalities, 51) telomere disease, 52,53) sensory organ disorder, 54) and storage disease.…”

Section: Generation Of Patient-specific Ipscsmentioning

confidence: 99%

Novel Insights into Disease Modeling Using Induced Pluripotent Stem Cells

Egashira

Yuasa

Fukuda

2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Induced pluripotent stem cell (iPSC) technology has great potential to establish novel therapeutic approaches in regenerative medicine and disease analysis. Although cell therapy using iPSC-derived cells still has many hurdles to overcome before clinical applications, disease analysis using patient-specific iPSCs may be of practical use in the near future. There are several reports that patient-specific iPSC-derived cells have recapitulated the apparent cellular phenotypes of a wide variety of diseases. Moreover, some studies revealed that it could be possible to discover effective new drugs and to clarify disease pathogenesis by examination of patient-specific iPSC-derived cells in vitro. We have recently reported that iPSCs can be a diagnostic tool in a patient with a novel mutation. For definitive diagnosis in a patient with long QT syndrome who had an uncharacterized genetic mutation, we succeeded in clarifying the patient's cellular electrophysiologic characteristics and the molecular mechanism underlying the disease phenotype through the multifaceted analyses of patient-specific iPSC-derived cardiomyocytes. In this review, we focus on the conceptual and practical issues in disease modeling using patient-specific iPSCs and discuss future directions in this research field.

show abstract

“…Since the invention of this method, iPSCs have been established from a variety of somatic cells not only for regenerative medicine but also for studies of the pathogenesis of inherited genetic disease 2-5 or neoplasms [6][7][8][9] . In term of the establishment of iPSCs from blood cells, the T cells that were derived from antigen-specific CD8 + T cells in an HIV-1-infected patient 10 , or from mature cytotoxic T cells that were specific for the melanoma epitope MART-1 11 , were reprogramed into iPSC, and were then re-differentiated into CD8…”

mentioning

confidence: 99%

Establishment of induced pluripotent stem cells from normal B cells and inducing AID expression in their differentiation into hematopoietic progenitor cells

Sakai

2017

Electrophoresis Letters

View full text Add to dashboard Cite

Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs)1 by exogenous expression of reprogramming factors (Yamanaka factors) such as Oct4, Sox2, Klf4 and c-Myc. Since the invention of this method, iPSCs have been established from a variety of somatic cells not only for regenerative medicine but also for studies of the pathogenesis of inherited genetic disease 2-5 or neoplasms [6][7][8][9] . In term of the establishment of iPSCs from blood cells, the T cells that were derived from antigen-specific CD8 + T cells in an HIV-1-infected patient 10 , or from mature cytotoxic T cells that were specific for the melanoma epitope MART-1 11 , were reprogramed into iPSC, and were then re-differentiated into CD8+ cells that possessed antigen-specific killing activity for treatment of patients with AIDS or melanoma, respectively. The important point of these studies is that the rearrangement of the T cell receptor (TCR) of the established T cell derived iPSC (TiPSC) was the same as that

show abstract

Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples

Cited by 145 publications

References 56 publications

Using induced pluripotent stem cells as a tool for modelling carcinogenesis

Using induced pluripotent stem cells as a tool for modelling carcinogenesis

Novel Insights into Disease Modeling Using Induced Pluripotent Stem Cells

Establishment of induced pluripotent stem cells from normal B cells and inducing AID expression in their differentiation into hematopoietic progenitor cells

Contact Info

Product

Resources

About